Dr. Pandalai on Outcomes With Adjuvant HIPEC in CRC

Prakash Pandalai, MD, discusses outcomes with adjuvant hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer.

Prakash Pandalai, MD, an ​assistant professor of surgery and surgical oncologist at the University of Kentucky Markey Cancer Center, discusses outcomes with adjuvant hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with colorectal cancer (CRC).

The phase 3 COLOPEC trial examined the use of adjuvant HIPEC as a way to prevent peritoneal recurrence in patients who have a high risk of carcinomatosis development, according to Pandalai. This was a European, multi-institutional trial that included high-risk patients who were found to have peritoneal carcinomatosis or high-risk features. 

However, investigators found no significant advantages in terms of disease-free survival or recurrence in the patients who received adjuvant HIPEC, concludes Pandalai.